Oxybutynin chloride - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for oxybutynin chloride and what is the scope of patent protection?

Oxybutynin chloride is the generic ingredient in four branded drugs marketed by Abbvie, Chartwell Rx, Ortho Mcneil Janssen, Lannett Co Inc, Pharm Assoc, Pharmobedient Cnsltg, Janssen Pharms, Accord Hlthcare, Ajanta Pharma Ltd, Amneal Pharms, Bionpharma, Impax Pharms, Norvium Bioscience, Osmotica Pharm Us, Rubicon, Unique, Zydus Pharms, Abhai Llc, Avet Lifesciences, Beximco Pharms Usa, Hibrow Hlthcare, Leading, Novast Labs, Novitium Pharma, Quantum Pharmics, Rising, Strides Pharma, Teva Pharms Usa, Trupharma, Upsher Smith Labs, Usl Pharma, and Watson Labs, and is included in thirty-eight NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Oxybutynin chloride has twenty-two patent family members in thirteen countries.

There are nine drug master file entries for oxybutynin chloride. Forty suppliers are listed for this compound.

Summary for oxybutynin chloride

International Patents:	22
US Patents:	3
Tradenames:	4
Applicants:	32
NDAs:	38
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	40
Raw Ingredient (Bulk) Api Vendors:	111
Clinical Trials:	23
Patent Applications:	2,577
Drug Prices:	Drug price trends for oxybutynin chloride
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for oxybutynin chloride
What excipients (inactive ingredients) are in oxybutynin chloride?	oxybutynin chloride excipients list
DailyMed Link:	oxybutynin chloride at DailyMed

See drug prices for oxybutynin chloride

Drug Sales Revenue Trends for oxybutynin chloride

See drug sales revenues for oxybutynin chloride

Recent Clinical Trials for oxybutynin chloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Seoul National University Hospital	Phase 2
Il-Yang Pharm. Co., Ltd.	Phase 2
National Cancer Institute (NCI)	Phase 2

See all oxybutynin chloride clinical trials

Pharmacology for oxybutynin chloride

Drug Class	Cholinergic Muscarinic Antagonist
Mechanism of Action	Cholinergic Muscarinic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for oxybutynin chloride

G04BD	Drugs for urinary frequency and incontinence
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for OXYBUTYNIN CHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GELNIQUE	Gel	oxybutynin chloride	10%	022204	1	2014-06-19

US Patents and Regulatory Information for oxybutynin chloride

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharm Assoc	OXYBUTYNIN CHLORIDE	oxybutynin chloride	SYRUP;ORAL	075137-001	Dec 18, 1998		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Zydus Pharms	OXYBUTYNIN CHLORIDE	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	202332-002	Jun 26, 2017	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Zydus Pharms	OXYBUTYNIN CHLORIDE	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	202332-001	Jun 26, 2017	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Rising	OXYBUTYNIN CHLORIDE	oxybutynin chloride	TABLET;ORAL	209025-002	Feb 7, 2023		RX	No	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Pharm Assoc	OXYBUTYNIN CHLORIDE	oxybutynin chloride	SYRUP;ORAL	074997-001	Oct 15, 1997		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Beximco Pharms Usa	OXYBUTYNIN CHLORIDE	oxybutynin chloride	TABLET;ORAL	213550-001	Jul 14, 2022	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for oxybutynin chloride

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-003	Jun 22, 1999	⤷ Sign Up	⤷ Sign Up
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-001	Dec 16, 1998	⤷ Sign Up	⤷ Sign Up
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-001	Dec 16, 1998	⤷ Sign Up	⤷ Sign Up
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-003	Jun 22, 1999	⤷ Sign Up	⤷ Sign Up
Abbvie	GELNIQUE	oxybutynin chloride	GEL;TRANSDERMAL	022204-001	Jan 27, 2009	⤷ Sign Up	⤷ Sign Up
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-002	Dec 16, 1998	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for oxybutynin chloride

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Germany	10772664		⤷ Sign Up
China	102421411	A method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions	⤷ Sign Up
Japan	2012526124		⤷ Sign Up
Japan	5795817		⤷ Sign Up
Brazil	PI1015542	um método para tratar bexigas hiperativas e um dispositivo para armazenamento e administração de composições tópicas de oxibutinina	⤷ Sign Up
Mexico	338166	UN PROCEDIMIENTO PARA TRATAR VEJIGAS HIPERACTIVAS Y UN DISPOSITIVO PARA ALMACENAMIENTO Y ADMINISTRACION DE COMPOSICIONES TOPICAS DE OXIBUTININA. (A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS.)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.